138 related articles for article (PubMed ID: 11069321)
1. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders.
Sagar M; Bertilsson L; Stridsberg M; Kjellin A; Mârdh S; Seensalu R
Aliment Pharmacol Ther; 2000 Nov; 14(11):1495-502. PubMed ID: 11069321
[TBL] [Abstract][Full Text] [Related]
2. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment.
Sagar M; Janczewska I; Ljungdahl A; Bertilsson L; Seensalu R
Aliment Pharmacol Ther; 1999 Apr; 13(4):453-8. PubMed ID: 10215728
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
[TBL] [Abstract][Full Text] [Related]
8. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
10. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
11. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Furuta T; Ohashi K; Kamata T; Takashima M; Kosuge K; Kawasaki T; Hanai H; Kubota T; Ishizaki T; Kaneko E
Ann Intern Med; 1998 Dec; 129(12):1027-30. PubMed ID: 9867757
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
13. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Bloemena E; Nelis GF; Festen HP; Jansen EH; Biemond I; Lamers CB; Meuwissen SG
Aliment Pharmacol Ther; 1998 Jul; 12(7):605-12. PubMed ID: 9701523
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
15. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
[TBL] [Abstract][Full Text] [Related]
17. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
19. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
20. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
